STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Whole-cell tumor vaccines aim to elicit T-cell responses but have limited success.
• Developing effective cancer vaccines remains a significant challenge in oncology.

Purpose of the Study:

• To evaluate the immunogenicity of hepatocellular carcinoma (HCC) cells modified by blocking the STAT3 signaling pathway.
• To assess the potential of STAT3-blocked HCC cell lysates as a whole-cell cancer vaccine.

Main Methods:

• Hepatocellular carcinoma (HCC) cell lines (H22 and Hepa1-6) were modified using a STAT3 decoy oligodeoxynucleotide to block the STAT3 signaling pathway.
• The immunogenicity and vaccine potential of these modified whole HCC cell lysates were evaluated in preclinical models.

Main Results:

• STAT3-blocked HCC cell lysates significantly inhibited tumor growth, reduced tumorigenesis, and prolonged survival in tumor-bearing mice.
• The vaccine stimulated T-cell and NK-cell activation, enhanced cytotoxic CD8+ T-cell infiltration, and promoted dendritic cell maturation, leading to immunological memory.
• Immunization reduced regulatory T-cells (Tregs) and immunosuppressive cytokines (TGF-β, IL-10), prevented T-cell and NK-cell exhaustion by lowering checkpoint molecule expression (PD-1, TIGIT), and primed robust secondary immune responses.

Conclusions:

• STAT3-blocked whole HCC cell lysates represent a promising new strategy for cancer cell vaccination.
• This approach enhances anti-tumor immunity and overcomes key immunosuppressive mechanisms in HCC.